Goldman Sachs Group Inc Oncorus, Inc. Transaction History

Goldman Sachs Group Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 14, 2024	SELL	$0.28 - $0.45 $1,958 - $3,147	-6,994 Reduced 40.69%	10,195 $3,000
Q1 2023 May 11, 2023	SELL	$0.28 - $0.45 $1,958 - $3,147	-6,994 Reduced 40.69%	10,195 $3,000
Q4 2022 May 14, 2024	SELL	$0.24 - $0.76 $1,733 - $5,488	-7,222 Reduced 29.59%	17,189 $4,000
Q4 2022 Feb 13, 2023	SELL	$0.24 - $0.76 $1,733 - $5,488	-7,222 Reduced 29.59%	17,189 $4,000
Q3 2022 May 14, 2024	SELL	$0.85 - $1.65 $79,486 - $154,298	-93,514 Reduced 79.3%	24,411 $21,000
Q3 2022 Nov 10, 2022	SELL	$0.85 - $1.65 $79,486 - $154,298	-93,514 Reduced 79.3%	24,411 $0
Q2 2022 May 14, 2024	BUY	$1.04 - $1.86 $122,642 - $219,340	117,925 New	117,925 $148,000
Q2 2022 Aug 15, 2022	BUY	$1.04 - $1.86 $31,894 - $57,042	30,668 Added 35.15%	117,925 $148,000
Q1 2022 May 16, 2022	SELL	$1.44 - $5.62 $29,417 - $114,810	-20,429 Reduced 18.97%	87,257 $155,000
Q4 2021 Feb 14, 2022	BUY	$5.03 - $11.63 $151,277 - $349,772	30,075 Added 38.75%	107,686 $568,000
Q3 2021 Nov 10, 2021	BUY	$9.29 - $14.27 $721,006 - $1.11 Million	77,611 New	77,611 $725,000

Ticker ONCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,973,100
Description
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various canc...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.